Concepedia

Aymen Elfiky

AE

Statistics

Publications

23

Citations

1.7K

H-Index

18

Active since

2006

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Brigham and Women's Hospital

Dana-Farber Brigham Cancer Center

Yale University

Aymen Elfiky is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and prostate cancer.

Publications per year

2006–2024

23

Publications

23

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

David C. Smith, Matthew R. Smith, Christopher J. Sweeney et al. · Journal of Clinical Oncology · 2012 · 443 citations · Full text

, , +13

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

Nikhil Wagle, Brian C. Grabiner, Eliezer M. Van Allen et al. · Cancer Discovery · 2014 · 281 citations · Full text

, , +17

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

Matthew R. Smith, Christopher J. Sweeney, Paul G. Corn et al. · Journal of Clinical Oncology · 2014 · 129 citations · Full text

, , +15

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

Maha Hussain, Matthew Ryan Smith, C. Sweeney et al. · Journal of Clinical Oncology · 2011 · 110 citations

, , +17

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study

André P. Fay, Sabina Signoretti, Marcella Callea et al. · Journal for ImmunoTherapy of Cancer · 2015 · 90 citations · Full text

, , +17

1–5 of 23